The global tuberculosis burden remains substantial, with more than 10 million people newly
ill per year. Nevertheless, tuberculosis incidence has slowly declined over the past decade …

Together, SARS-CoV-2 and M. tuberculosis have killed approximately 5.7 million people
worldwide over the past 2 years. The COVID-19 pandemic, and the non-pharmaceutical …

Abstract Type-1 and type-3 interferons (IFNs) are important for control of viral replication;
however, less is known about the role of Type-2 IFN (IFNγ) in anti-viral immunity. We …

Summary The ClpC1: ClpP1P2 protease is a core component of the proteostasis system in
mycobacteria. To improve the efficacy of antitubercular agents targeting the Clp protease …

Viral co-infections have been implicated in worsening tuberculosis (TB) and during the
COVID-19 pandemic, the global rate of TB-related deaths has increased for the first time in …

Background: There were global concerns and predictions that Coronavirus disease 2019
(COVID-19) would severely affect tuberculosis (TB) care and treatment services in resource …

Coronavirus disease-2019 (COVID-19), caused by SARS-CoV-2, is an infectious disease
that poses severe threats to global public health and significant economic losses. The …

Background and aim Patients with COVID-19 and tuberculosis coinfection are at an
increased risk of severe disease and death. We therefore sought to evaluate the current …

Background: We aimed to visualize and classify the time series of COVID-19, tuberculosis
(TB) notification, and TB outcomes (cure, treatment abandonment, and death), verify the …

Tuberculosis (TB) is a major cause of ill health worldwide. Until the coronavirus (COVID-19)
pandemic, TB was the leading cause of death from a single infectious agent. COVID-19 has …